Azitra announces 1-for-6.66 reverse stock split effective August 21

NEW YORK - Azitra, Inc. (NYSE American:AZTR), a clinical-stage biopharmaceutical company focused on developing therapies for precision dermatology, announced Monday it will implement a 1-for-6.66 reverse stock split effective August 21, 2025. The announcement comes as the stock trades near its 52-week low of $0.16, having declined over 75% in the past year. InvestingPro analysis suggests the stock is currently in oversold territory.

The company’s common stock will continue trading on the NYSE American under the symbol "AZTR" but will begin trading on a split-adjusted basis when markets open on August 21, just days after its upcoming earnings release scheduled for August 18. The new CUSIP number will be 05479L302.

The reverse split will reduce Azitra’s outstanding common shares from approximately 23.5 million to 3.5 million shares. The company’s board of directors approved the final split ratio on August 7, following stockholder authorization granted at a special meeting on February 20.

According to the company’s statement, the reverse split will not alter any stockholder’s percentage interest in Azitra’s equity, except where fractional shares result. Stockholders entitled to fractional shares will receive cash in lieu of these fractions.

Proportional adjustments will be made to the number of shares issuable upon exercise or conversion of equity awards and warrants, as well as their exercise prices.

Stockholders holding shares through brokerage accounts will have their shares automatically adjusted to reflect the split. Those holding certificated shares are not required to exchange their existing stock certificates, though they may do so if desired.

The announcement is based on information provided in a company press release.

In other recent news, Azitra, Inc. shareholders have approved an amendment to the company’s certificate of incorporation to double the authorized number of common shares from 100 million to 200 million. This decision was reached at a reconvened annual meeting, following an earlier adjournment to allow more time for voting on the proposal. The amendment was adopted with 1,090,701 shares voting in favor and 278,960 against, while 2,607 shares abstained. Additionally, Azitra announced progress in its Phase 1b clinical trial for ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial has reached 50% enrollment and reports encouraging safety data. No severe or serious adverse events have been observed, with only mild to moderate symptoms reported at application sites. These symptoms include localized itch, redness, and burning sensations, which appear to be transient. The company continues to monitor the trial closely as it progresses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.